Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Work In Process (2020 - 2025)

Historic Work In Process for Puma Biotechnology (PBYI) over the last 6 years, with Q3 2025 value amounting to $5.4 million.

  • Puma Biotechnology's Work In Process rose 16907.73% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 16907.73%. This contributed to the annual value of $758000.0 for FY2024, which is 756.1% down from last year.
  • Puma Biotechnology's Work In Process amounted to $5.4 million in Q3 2025, which was up 16907.73% from $1.3 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Work In Process high stood at $7.8 million for Q2 2024, and its period low was $758000.0 during Q4 2024.
  • For the 5-year period, Puma Biotechnology's Work In Process averaged around $2.6 million, with its median value being $2.1 million (2024).
  • Data for Puma Biotechnology's Work In Process shows a peak YoY increase of 16907.73% (in 2025) and a maximum YoY decrease of 8288.91% (in 2025) over the last 5 years.
  • Puma Biotechnology's Work In Process (Quarter) stood at $1.4 million in 2021, then surged by 92.13% to $2.7 million in 2022, then crashed by 69.18% to $820000.0 in 2023, then fell by 7.56% to $758000.0 in 2024, then skyrocketed by 611.74% to $5.4 million in 2025.
  • Its Work In Process stands at $5.4 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.1 million for Q1 2025.